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Background: Patient involvement is widely acknowledged to be a valuable component in
health technology assessment (HTA) and healthcare decision making. However,
quantitative approaches to ascertain patients’ preferences for treatment endpoints are not
yet established. The objective of this study is to introduce the analytic hierarchy process
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(AHP) as a preference elicitation method in HTA. Based on a systematic literature review
on the use of AHP in health care in 2009, the German Institute for Quality and Efficiency
in Health Care (IQWiG) initiated an AHP study related to its HTA work in 2010.
Methods: The AHP study included two AHP workshops, one with twelve patients and one
with seven healthcare professionals. In these workshops, both patients and professionals
rated their preferences with respect to the importance of different endpoints of
antidepressant treatment by a pairwise comparison of individual endpoints. These
comparisons were performed and evaluated by the AHP method and relative weights
were generated for each endpoint.
Results: The AHP study indicates that AHP is a well-structured technique whose
cognitive demands were well handled by patients and professionals. The two groups rated
some of the included endpoints of antidepressant treatment differently. For both groups,
however, the same six of the eleven endpoints analyzed accounted for more than
80 percent of the total weight.
Conclusions: AHP can be used in HTA to give a quantitative dimension to patients’
preferences for treatment endpoints. Preference elicitation could provide important
information at various stages of HTA and challenge opinions on the importance of
endpoints.
Keywords: Patient involvement, Patient preferences, Analytic hierarchy process (AHP),
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In the past few years, patient involvement and participation
have been increasingly introduced in health technology as-
sessment (HTA) and the resulting decision-making processes
in various jurisdictions around the world. But why is it so im-
portant to incorporate patients’ views into HTA, and where
and how can this best be done? A survey by the International
Network of Agencies for Health Technology Assessment
(INAHTA) conducted in 2006 concluded that the involve-
ment of “consumers” in the assessment and decision-making
processes within HTA agencies “broadens the perspective
of those assessments and of the advice provided to decision
makers” (9). In the survey, the term “consumers” included
“patients, carers, long-term users of services, organizations
representing consumers’ interests, and members of the public
who are potential recipients of health promotion programs.”
According to Facey et al. (8), “patients can provide a real
world understanding of the illness / condition, and the bene-
fits and disbenefits of using particular technologies.” Given
that patients are the ultimate “end-users” of health technolo-
gies, patient involvement in HTA processes may therefore
increase acceptance of HTA and the viability of resulting
healthcare decisions.
Patients can be involved at various levels in healthcare
decision making, that is, at the micro-, meso-, or macro-level,
as experts on their own health. At the micro-level, patients
can, for example, participate in shared decision making with
their healthcare professionals (23). HTA agencies play a key
role at the meso-level, often formulating recommendations as
to which technologies should be implemented. Their recom-
mendations may have a direct impact on healthcare policy
and reimbursement decisions taken at the macro-level. At
these levels, opportunities for patient participation exist and
are being continuously explored (4;8;23;25).
There are at least three approaches to the inclusion of pa-
tients’ views in HTA processes (8;18). First, patients or their
representatives can be involved as members in committees
and actively contribute to an HTA agency’s work processes.
Alternatively or additionally, in many countries patients or
patient groups are invited to comment on specific issues. Sec-
ond, certain qualitative methods (e.g., individual in-depth or
focus group interviews, consensus panels) may enable re-
searchers and decision makers in HTA agencies to assess
and include patients’ views in a more systematic and struc-
tured manner (e.g., patients as members in DELPHI panels
to formulate guideline recommendations). Third, quantita-
tive methods can be used to “measure” patient preferences.
For example, the QALY approach, which is predominantly
used in health economic evaluation within HTA, is based ei-
ther on direct elicitation of patient preferences by Standard
Gamble, Time Trade-Off and Visual Analogue Scales, or in-
directly, by applying generic instruments such as the EQ-5D.
Patient involvement in HTA agencies has been implemented
to a differing degree in the first two approaches. In the IN-
AHTA survey (9), twenty-one of the thirty-seven agencies in-
volved consumers in several aspects of their HTA programs,
for example, in the formulation of assessment topics or in
their topic-prioritizing process. A quantification of patient-
preferences in the form of utilities (QALY approach) or in
monetary terms (willingness-to-pay [WTP] approaches) and
integration into health economic evaluations, that is, cost-
utility or cost-benefit analyses, is currently standard in many
HTA agencies.
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The purpose of this study is to introduce the analytic
hierarchy process (AHP) as a means of quantifying patient
preferences in a new area within the HTA process: to priori-
tize and weight patient-relevant endpoints for assessment in
HTA reports to explore whether the method could be used in
IQWiG’s benefit- or cost-effectiveness-assessments. First, an
AHP study related to two reports by the German Institute for
Quality and Efficiency in Health Care (IQWiG) is presented
and discussed. Second, further possible areas of application
of AHP within HTA are outlined.
THE AHP METHOD: AN INTRODUCTION
Multi-criteria decision analysis (MCDA) is what basically
happens in many everyday consumer decisions, in which the
different characteristics of a product are taken into account
and weighed against each other, for example, the design,
color, and gasoline consumption of a new car. MCDA can
be used to support decision making in health care and to
elicit patient preferences and values in complex decision-
making contexts (3;5–7;16;24). AHP is a MCDA technique
developed by the mathematician Thomas Saaty in the 1970s
(19;20). It was introduced to support strategic decisions in in-
dustry. AHP is an approach where a multi-attribute decision
problem is first structured into a hierarchy of interrelated
elements (17). This hierarchy is a tree-like structure that
is used to decompose the decision problem, moving from
main criteria to more specific sub- and “sub-sub”-criteria.
Pairwise comparisons of these criteria are separately per-
formed at each level of a decision hierarchy, moving through
each group of criteria in the hierarchy from the lower-level
to the upper-level criteria. Important methodological con-
straints within AHP regarding the decision hierarchy are the
independence and comprehensiveness of criteria at each level
(20). Based on matrices of the pairwise comparisons, Saaty’s
mathematical algorithm as a key element within AHP allows
the calculation of an approximative vector (“right eigenvec-
tor”) representing preference-based weights for each of the
decision criteria included (7;20). While the preferences in
AHP are recorded on a numbered but ordinal scale, calcula-
tion of preference weights is performed by transforming this
scale into an approximative cardinal one. For details on the
calculation of the eigenvector by means of different matrix
multiplication methods, see in particular Dolan et al. 1989
(7).
Based on the weights calculated for each endpoint in-
cluded for each person, a group geometric mean can be cal-
culated for a group of individuals taking part in the AHP. In
addition, because reciprocity and transitivity of preferences
is required within AHP, AHP allows for calculation of a mea-
sure of consistency for each group of pairwise comparisons.
This measure reflects how logical each pairwise comparison
is with regard to the remainder of comparisons performed by
the same individual. For example, an individual rating A >
B, B > C, and C > A would be inconsistent in his or her
judgments. This consistency ratio (CR), as a measure of per-
formance within the AHP, has a threshold of 0.1 that should
not be exceeded (7).
USE OF AHP IN HEALTH CARE
In 2009, IQWiG commissioned a systematic literature re-
view to obtain information on how and where AHP was
used in healthcare decision making. Eighty-five articles were
identified of which fifty-five reported on specific applica-
tions of AHP in different decision-making contexts (10).
Of these, 44 percent focused on management decisions in
healthcare organizations, 25 percent on the development of
clinical guidelines, 13 percent, respectively, on shared de-
cision making and the development of national healthcare
policy, and 5 percent on the development of healthcare in-
novations. The review supported the notion that AHP was
a well-structured decision-making tool, which was easy-to-
handle for different groups of individuals participating in the
pairwise-comparison procedures. It should be noted in this
context, however, that AHP has also repeatedly been sub-
ject to methodological criticism, for example, with regard
to the preference scales used in AHP or to issues of rank
reversal (e.g., (1;2)). Different approaches to the solution of
these problems have been suggested or are being explored
(1;15;21;22).
METHODS
Patients with a previous diagnosis of major depression, but
currently in remission, were recruited by means of German
self-help and patient interest groups contacted by the re-
spective department at the German Federal Joint Committee.
Patients were invited to participate in IQWiG’s AHP work-
shops by means of patient group websites. Professionals in-
volved in the care of patients with depression (psychiatrists,
other specialized physicians, and psychotherapists working
in private practice or hospitals) were identified and recruited
by means of German scientific societies as well as Internet
search engines.
Patients and professionals participating in the moderated
AHP workshops were asked to compare pairs of treatment
endpoints and score them using radio-controlled keypads.
Participants had to rate the importance of one endpoint com-
pared with another on a scale ranging from 1 (reflecting
equal importance of the two endpoints) up to 9 (reflect-
ing extremely greater importance of one endpoint over the
other). One example of a pairwise comparison is displayed in
Figure 1. Professionals in the AHP professional workshop
were asked to rate endpoints according to which ones they
considered more important in the care of their patients. The
study focused on endpoints of antidepressant treatment that
had previously been assessed in two IQWiG benefit as-
sessments (12;13). Endpoint selection was based on prede-
fined decision criteria, primarily the strength of the available
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9 7 5 3 1 3 5 7 9
Reduction of anxiety Equal importance Reduction of pain
1   -    equally important
3   -    slightly more important
5   -    more important
7   -    much more important
9   -    extremely more important 
Figure 1. Example of a pairwise comparison of two quality-of-life-related treatment endpoints rated on a 9-point scale.
clinical evidence supporting the endpoint as well as method-
ological constraints of AHP (especially comprehensiveness
and independence of decision criteria).
In preparation of the AHP workshops, interviewees re-
ceived written information on which treatment endpoints
were to be included in the workshops and how these were
defined. Patients received these explanations of endpoints
in lay language. Because the definition of the endpoints in-
cluded and a common understanding among participants of
what they mean are crucial, questions regarding definitions
were addressed before the initiation of the pairwise compar-
ison procedures. The definition of endpoints was based on
the definitions in the IQWiG benefit assessments, for exam-
ple, the endpoint “response” was defined as achieving a 50
percent reduction of symptoms in an acute episode of depres-
sion. Based on all pairwise comparisons, individual weights
for each endpoint were calculated with Saaty’s mathematical
method (right eigenvector) and the group (geometric) means
were then generated separately for the group of patients and
the group of professionals (7).
In the workshops, each pairwise comparison between
endpoints was accompanied by a short discussion of individ-
ual ratings within the respective group. These group discus-
sions facilitated understanding of the motivation of patients
and professionals as to why they considered one endpoint
more or less important than another one. Furthermore, each
pairwise comparison was followed by a “consistency check,”
that is, the CR was calculated as a measure of performance
within AHP. The calculation of weights and the respective
CRs were performed by means of the software package Ex-
pert Choice 11.
RESULTS
Twelve patients and seven professionals participated in the
AHP patient workshop and professional workshop, respec-
tively. Table 1 contains the patient-based and professional-
based weights for each individual outcome measure.
Table 1. Priorities of Patients and Professionals Regarding
Endpoints of Antidepressant Treatment
Patient-relevant
outcome measure
Group priority
Patients
Group priority
Professionals (position
in rank order)
Response 0.324 0.061 (5)
Improvement of
cognitive function
0.125 0.062 (4)
Reduction of anxiety 0.118 0.054 (6)
Improvement of social
function
0.107 0.090 (3)
Avoidance of relapse 0.091 0.144 (2)
Remission 0.085 0.475 (1)
Reduction of pain 0.054 0.033 (7)
No other serious
adverse events
0.039 0.029 (8)
No (attempted) suicide 0.026 0.022 (9)
No other adverse events 0.023 0.020 (10)
No sexual dysfunction 0.007 0.007 (11)
“Response” was rated the most important endpoint by the
group of patients, followed by the endpoint “improvement of
cognitive function.” The endpoint “remission” received the
highest weighting within the group of professionals, followed
by “avoidance of relapse.” The professionals rated “sexual
dysfunction” lowest, as did the patients. In both workshop
groups, there was good consistency in the results (CR< 0.1).
The set of the six most important patient-relevant outcome
measures was the same for both groups. Three of these are
related to efficacy: response, remission, and no relapse. Three
are related to different aspects of quality of life: improvement
of social functioning, improvement of cognitive function and
reduction of anxiety. These six endpoints covered 85 percent
of the overall weights in the patient group and 89 percent in
the professional group.
The group discussions held in between the pairwise com-
parisons offered an insight into the question as to why certain
outcome measures were more important to patients and pro-
fessionals than others. For example, while patients in an acute
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episode of major depression focused on a fast response and
relief, professionals stated a preference for full remission
and prevention of relapse. The results should not, however,
be interpreted as a lack of interest by patients in reaching
full remission. The patients’ vote can be understood as a
preference for a drug that helped to achieve a fast response
over a drug that would be less effective in this regard, but
more effective in reaching full remission after some time. Pa-
tients explained this by their experience that most will never
function fully again, so that the rapid attainment of a mod-
erate level of functioning in an acute episode of depression
would be of more value. Group discussions also showed that
the criteria and sub-criteria related to the adverse effects of
antidepressants were—when traded off against efficacy or
quality-of-life endpoints, considered either “of less conse-
quence” (minor adverse events) or infrequent and therefore
posing a “less immediate threat” (serious adverse events such
as suicide).
DISCUSSION
This study indicated that the AHP method for pairwise com-
parisons of individual treatment endpoints was well handled
by patients and professionals. It also delivered consistent re-
sults regarding the generation of preference-based weights.
Finally, it provided valuable insights into the interviewees’
reasoning as to why they considered certain endpoints more
(or less) important than others. While the study focused on
the elicitation of patient preferences, the AHP results for
professionals helped to detect deviances from what patients
consider important in their treatment. The inclusion of the
professional group was considered important to contrast the
results of both groups. With its small sample size (twelve
patients and seven professionals), the study did not aim to
deliver representative results, but to explore the AHP method
as a practical tool in the quantification of preferences with
respect to treatment endpoints. It is, however, notable in this
context that AHP workshops are most effectively organized
with small groups of individuals (twenty at most), allow-
ing for effective group discussions to be held in between
pairwise comparisons. To make AHP more representative, a
precise definition of the subgroup of patients to be targeted
would first be needed or stratified workshops (e.g., by age
or gender) would need to be conducted. In addition, patient
workshops in different regions of Germany could be held to
increase the overall number of participants and to produce a
better geographic representation of patients. In addition to the
in-person workshops, an Internet-based elicitation of prefer-
ences could be considered. However, the resources required
to conduct AHP surveys in the proposed manner would need
to be further explored before extending its application.
A major challenge in this study was the selection of
endpoints from the IQWiG benefit assessments for inclu-
sion in the AHP decision hierarchy. While the set of criteria
should be as comprehensible as possible in such hierarchy,
conceptional overlap between criteria should be minimized.
Because some degree of overlap is inherent in many of the
endpoints of antidepressant treatment (e.g., functional im-
pairment is likely to be associated with anxiety), complete
avoidance of overlap was impossible. Providing a very pre-
cise definition of each endpoint traded-off against each other
in the pairwise comparisons helped reduce the potentially
negative effects of overlap that might result in an overes-
timation of a particular endpoint in the final weights (e.g.,
anxiety in the example above).
Although there are different quantitative methods for
eliciting patients’ preferences in the form of utilities (e.g.,
QALY approach) and contingent valuation methods (e.g.,
WTP) in health economic evaluation within HTA, these
methods require patients to state their preferences regard-
ing their health status in aggregate. In contrast, methods for
eliciting patient preferences such as the AHP allow for a
decompositional valuation of health status by extracting and
highlighting the important elements. They permit a reduction
in the number of trade-offs to be made at one time by a patient
in a complex decision setting to a choice between only two
decision criteria in each pairwise comparison within AHP. A
strength of the AHP method is the reduced cognitive burden
for the patient by decomposing a complex decision problem
into a limited number of pairwise comparisons.
The validity of AHP in the context of utility theory and
in comparison with other preference assessment tools, such
as conjoint analysis, has also been discussed (11;14). While a
full discussion of this issue would go beyond the scope of this
study, one advantage of AHP may even be that interviewees
do not have to comply with the characteristics of the so called
“homo-economicus.” The pairwise comparison of criteria is
in accordance with human behavior, especially if it is based
on bounded rationality. Saaty’s method of deriving priorities
from pairwise comparisons based on matrix multiplication
and the eigenvector calculation is mathematically sophisti-
cated. Moreover, AHP provides for control of the logic and
quality of decisions by using the inconsistency ratio to check
for stability of rankings. A weakness of the method, however,
is in particular the risk of rank reversal, for example, when
adding or removing decision criteria.
While patients should be involved in HTA to some de-
gree and at different stages of an assessment and the re-
sulting decision-making processes, AHP (or another MCDA
method) would most likely be restricted to situations where
a quantification of patient preferences can precede or be di-
rectly integrated into the HTA and its results, for example,
by selecting, prioritizing, or weighting patient-relevant end-
points of treatment. In Germany, prioritization of HTA as-
sessment topics, as well as the appraisal and decision making
for the statutory health insurance, take place at the level of a
body called the Federal Joint Committee. AHP may be appli-
cable here. Furthermore, the AHP method could help decide
which endpoints matter, even before an HTA (benefit assess-
ment) within IQWiG is started. AHP could also serve as a
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decision aid in determining which endpoints of an economic
evaluation should receive a higher (or lower) weighting in
the aggregation of results. In Germany, such an aggrega-
tion may be necessary to derive reimbursable prices for new
medications and could be part of IQWiG’s cost-effectiveness
evaluations.
Although AHP has primarily been developed to support
decision making, it may also play a role in (i) identifying or
prioritizing patient-relevant outcomes when clinical trials are
designed and (ii) analyzing the net benefit of health interven-
tions based on AHP results. In the first application, national
HTA institutions could provide advice to the pharmaceutical
industry as to which treatment endpoints are considered to be
of importance. In the second proposed area, it is possible to
determine weights for endpoints by developing a hierarchical
structure of the outcome measures considered and to base net
benefit assessments on these weighted outcome measures.
CONCLUSION
As patient involvement will be further strengthened in many
jurisdictions in the future, the consideration of tools such as
AHP is essential. Germany seems to be entering a new era
by moving toward full acknowledgment of patients’ prefer-
ences, and by increasing its consideration of different quali-
tative and quantitative methods for preference elicitation.
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